Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 8:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,488 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched placebo capsules Clear all
Terminated Phase 2 Interventional

Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

NCT00814372
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
MBX-102, Placebo, Actos, Metformin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
5
States / cities
Burbank, California • Los Angeles, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2730

NCT03054194
View directory record Official record
Conditions
Healthy Participants
Interventions
E2730, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2018 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 3 Interventional

Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

NCT01743651
View directory record Official record
Conditions
Spasticity, Multiple Sclerosis
Interventions
arbaclofen, baclofen, Placebo
Drug
Lead sponsor
RVL Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
25
States / cities
Cullman, Alabama • Long Beach, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy of SAGE-217 in the Treatment of Adult Participants With Major Depressive Disorder

NCT03672175
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
SAGE-217, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
53
States / cities
Rogers, Arkansas • Bellflower, California • Garden Grove, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Randomized, Placebo-controlled Trial of Lubiprostone as a Preparation for Capsule Endoscopy

NCT00746395
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
19 Years to 90 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 2 Interventional

Centella Asiatica Selected Triterpenes (CAST) for Diabetic Neuropathy

NCT00608439
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Centella asiatica selected triterpenes (CAST), Placebo
Drug · Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-6987 for the Treatment of Mild to Moderate Asthma

NCT01296087
View directory record Official record
Conditions
Asthma
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2013 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 2 Interventional

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

NCT02342249
View directory record Official record
Conditions
Influenza A
Interventions
VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
129
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK

NCT06269484
View directory record Official record
Conditions
Liver Cirrhosis
Interventions
Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 11, 2026, 8:28 AM EDT
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858
View directory record Official record
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 11, 2026, 8:28 AM EDT
Terminated Phase 2 Interventional Results available

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II

NCT05047185
View directory record Official record
Conditions
Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II, Hereditary Angioedema Types I and II, Hereditary Angioedema Attack, Hereditary Angioedema With C1 Esterase Inhibitor Deficiency, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, C1 Esterase Inhibitor Deficiency, C1 Inhibitor Deficiency
Interventions
Deucrictibant low dose, Deucrictibant high dose, Placebo
Drug
Lead sponsor
Pharvaris Netherlands B.V.
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
3
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

NCT02181413
View directory record Official record
Conditions
Multiple Myeloma, Autologous Stem Cell Transplant
Interventions
Ixazomib Citrate, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
6
States / cities
Little Rock, Arkansas • Rochester, Minnesota • The Bronx, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Centella Asiatica in Older Adults

NCT06472791
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Centella Asiatica, Placebo Comparator
Dietary Supplement
Lead sponsor
National University of Natural Medicine
Other
Eligibility
50 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects

NCT03698513
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BMS-986177, Placebo (for BMS-986177), Clopidogrel, Aspirin
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia
Interventions
rivaroxaban, placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 11, 2026, 8:28 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention

NCT04804033
View directory record Official record
Conditions
Migraine
Interventions
BHV-3500 (zavegepant), Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
1,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
116
States / cities
Phoenix, Arizona • Tucson, Arizona • Canoga Park, California + 88 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 1Phase 2 Interventional Results available

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT01075048
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Tivantinib, Placebo, Cetuximab, Irinotecan
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
24
States / cities
Beverly Hills, California • Encinitas, California • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT03482648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
BBT-401-1S, Single dose, BBT-401-1S, Multiple doses, Placebo
Drug
Lead sponsor
Bridge Biotherapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT03573908
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
79
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
QBW251, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Birmingham, Alabama • Fullerton, California • Waterbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 11, 2026, 8:28 AM EDT
Active, not recruiting Phase 2 Interventional

Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

NCT05510115
View directory record Official record
Conditions
Polycystic Kidney, Autosomal Dominant
Interventions
Empagliflozin, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 11, 2026, 8:28 AM EDT
Recruiting Phase 4 Interventional

Buspirone for Anxiety in Autistic Youth

NCT07439042
View directory record Official record
Conditions
Anxiety, Autism Spectrum Disorder
Interventions
buspirone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Lexington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 11, 2026, 8:28 AM EDT
Completed Phase 2 Interventional

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

NCT01271790
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Tegobuvir (GS-9190), GS-9451, Pegasys®, Copegus®, Tegobuvir placebo, GS-9451 placebo
Drug · Biological
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
85
States / cities
Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 11, 2026, 8:28 AM EDT